🇺🇸 FDA
Patent

US 7820162

Methods for chemically synthesizing immunoglobulin chimeric proteins

granted A61KA61K38/00A61K47/60

Quick answer

US patent 7820162 (Methods for chemically synthesizing immunoglobulin chimeric proteins) held by Syntonix Pharmaceuticals, Inc. expires Mon Oct 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Syntonix Pharmaceuticals, Inc.
Grant date
Tue Oct 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/00, A61K47/60, A61K47/642, A61K47/68